tetano
Editor, Senior Moderator
Dig Liver Dis
. 2020 Sep 17;S1590-8658(20)30472-2.
doi: 10.1016/j.dld.2020.09.007. Online ahead of print.
Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis
Lu Pan[SUP] 1 [/SUP], Pan Huang[SUP] 2 [/SUP], Xia Xie[SUP] 3 [/SUP], Jiachen Xu[SUP] 4 [/SUP], Dawei Guo[SUP] 4 [/SUP], Yuan Jiang[SUP] 5 [/SUP]
Affiliations
Abstract
Background: The association between metabolic-associated fatty liver disease (MAFLD) and disease progression in patients with the coronavirus disease 2019 (COVID-19) are unclear.
Aims: To explore the association between MAFLD and the severity of COVID-19 by meta-analysis.
Methods: We conducted a literature search using PubMed, EMBASE, Medline (OVID), and MedRxiv from inception to July 6, 2020. Newcastle-Ottawa Scale (NOS) and Stata 14.0 were used for quality assessment of included studies as well as for performing a pooled analysis.
Results: A total of 6 studies with 1,293 participants were included after screening. Four studies reported the prevalence of MAFLD patients with COVID-19, with a pooled prevalence of 0.31 for MAFLD (95CI 0.28, 0.35, I[SUP]2[/SUP] = 38.8%, P = 0.179). MAFLD increased the risk of COVID-19 disease severity, with a pooled OR of 2.93 (95CI 1.87, 4.60, I[SUP]2[/SUP] = 34.3%, P = 0.166).
Conclusion: In this meta-analysis, we found that a high percentage of patients with COVID-19 had MAFLD. Meanwhile, MAFLD increased the risk of disease progression among patients with COVID-19. Thus, better intensive care and monitoring are needed for MAFLD patients infected by SARS-COV-2.
Keywords: COVID-19; Metabolic associated fatty liver disease; SARS-CoV-2.
. 2020 Sep 17;S1590-8658(20)30472-2.
doi: 10.1016/j.dld.2020.09.007. Online ahead of print.
Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis
Lu Pan[SUP] 1 [/SUP], Pan Huang[SUP] 2 [/SUP], Xia Xie[SUP] 3 [/SUP], Jiachen Xu[SUP] 4 [/SUP], Dawei Guo[SUP] 4 [/SUP], Yuan Jiang[SUP] 5 [/SUP]
Affiliations
- PMID: 33011088
- PMCID: PMC7498251
- DOI: 10.1016/j.dld.2020.09.007
Abstract
Background: The association between metabolic-associated fatty liver disease (MAFLD) and disease progression in patients with the coronavirus disease 2019 (COVID-19) are unclear.
Aims: To explore the association between MAFLD and the severity of COVID-19 by meta-analysis.
Methods: We conducted a literature search using PubMed, EMBASE, Medline (OVID), and MedRxiv from inception to July 6, 2020. Newcastle-Ottawa Scale (NOS) and Stata 14.0 were used for quality assessment of included studies as well as for performing a pooled analysis.
Results: A total of 6 studies with 1,293 participants were included after screening. Four studies reported the prevalence of MAFLD patients with COVID-19, with a pooled prevalence of 0.31 for MAFLD (95CI 0.28, 0.35, I[SUP]2[/SUP] = 38.8%, P = 0.179). MAFLD increased the risk of COVID-19 disease severity, with a pooled OR of 2.93 (95CI 1.87, 4.60, I[SUP]2[/SUP] = 34.3%, P = 0.166).
Conclusion: In this meta-analysis, we found that a high percentage of patients with COVID-19 had MAFLD. Meanwhile, MAFLD increased the risk of disease progression among patients with COVID-19. Thus, better intensive care and monitoring are needed for MAFLD patients infected by SARS-COV-2.
Keywords: COVID-19; Metabolic associated fatty liver disease; SARS-CoV-2.